Nevertheless, due to the high dose of systemically administered IFNα, the side effect of cell toxicity is inevitable, and the short half-life of this protein also hinders it from reaching the desired concentration at tumor sites [6]. The gene discussed is IFNA17; the disease is neoplasm.